ルーマニア -
ルーマニア語 -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
maresyl 0,5 mg/ml
jadran-galenski laboratorij d.d. - croatia - xylometazolinum - spray naz.,sol. - 0,5mg/ml - decongestionante si alte medicamente nazale de uz topic simpatomimetice
ルーマニア -
ルーマニア語 -
ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)
maresyl 1 mg/ml
jadran-galenski laboratorij d.d. - croatia - xylometazolinum - spray naz.,sol. - 1mg/ml - decongestionante si alte medicamente nazale de uz topic simpatomimetice
欧州連合 -
ルーマニア語 -
EMA (European Medicines Agency)
ultomiris
alexion europe sas - ravulizumab - hemoglobinurie, paroxismal - imunosupresoare selective - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
欧州連合 -
ルーマニア語 -
EMA (European Medicines Agency)
enspryng
roche registration gmbh - satralizumab - neuromyelitis optica - imunosupresoare - satralizumab (enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (ist) for the treatment of neuromyelitis optica spectrum disorders (nmosd) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 igg (aqp4-igg) seropositive.
モルドバ -
ルーマニア語 -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
a-ferin forte 650 mg/4 mg comprimate filmate
bilim ilac sanayi ve ticaret a.Ș. - paracetamolum + chlorphenaminum - comprimate filmate - 650 mg/4 mg
モルドバ -
ルーマニア語 -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
metadone cloridrato molteni sugar free 5 mg/ml soluţie orală
l.molteni & c. dei f.lli alitti società di esercizio s.p.a. - metadona - soluţie orală - 5 mg/ml
モルドバ -
ルーマニア語 -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
fersinol-f 100 mg/0,35 mg comprimate
world medicine ltd - ferri (iii) hydroxidum cum polymaltosi complexum + acidum folicum - comprimate - 100 mg/0,35 mg
モルドバ -
ルーマニア語 -
AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)
trimetazidină lph 35 mg comprimate cu eliberare prelungită
labormed pharma s.a. - trimetazidinum - comprimate cu eliberare prelungită - 35 mg